Nasus Pharma is trading 5.73% down now at $3.85 amid global risk-off pressure, including rising rates and geopolitical concerns.

  • The S&P 500 is down 0.61%, while the Nasdaq Composite is down 1.03%.
  • No confirmed company-specific announcement dated September 1, 2026, has emerged.
  • The latest identified updates were the August 19 CFO transition and August 17 first-half results, making them stale explanations for today’s decline.